
Opinion|Videos|November 26, 2025
Treatment Primer on TNBC
Fact checked by: Nicole Canfora Lupo
This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.
Advertisement
Episodes in this series

Now Playing
Metastatic triple-negative breast cancer (mTNBC) presents a significant therapeutic challenge due to its aggressive nature and lack of hormone or HER2 targets. The current treatment algorithm emphasizes a personalized approach based on biomarker status, prior therapies, and patient health or clinical trial enrollment when available. Overall, treatment decisions are increasingly guided by molecular profiling and emerging biomarkers to optimize outcomes and balance efficacy with tolerability.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
5
















































































































